• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Harrow Inc.

    4/25/25 8:01:18 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email
    DEFA14A 1 formdefa14a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒   Filed by a Party other than the Registrant ☐  

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material Pursuant to §240.14a-12

     

    HARROW, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of person(s) filing proxy statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒No fee required
      
    ☐Fee paid previously with preliminary materials.
      
    ☐Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

     

     

     

     
     

     

     

     
     

     

     

     

     

     

    Get the next $HROW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    9/24/2021$15.00Buy
    Aegis Capital
    7/2/2021$14.25Buy
    Ladenburg Thalmann
    More analyst ratings

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harrow to Present at Two Investor Conferences in May

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA) Format: Fireside Chat, followed by 1x1 Investor Meetings Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025 Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN) Format: 1x1 and Small Group Investor Meetings Date/Time: Wednesday, May 28, 2025 Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum r

      5/14/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/25/24 5:19:24 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/24/24 4:40:20 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      4/19/24 6:24:32 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Harrow with a new price target

      H.C. Wainwright initiated coverage of Harrow with a rating of Buy and set a new price target of $57.00

      2/6/25 7:06:49 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on Harrow with a new price target

      B. Riley Securities reiterated coverage of Harrow with a rating of Buy and set a new price target of $69.00 from $73.00 previously

      12/4/24 8:02:39 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Harrow with a new price target

      Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00

      4/11/24 7:51:28 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Leadership Updates

    Live Leadership Updates

    See more
    • Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

      Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

      1/7/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

      5/13/24 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

      Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth

      3/6/23 8:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      12/5/24 7:08:52 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Harrow Inc.

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      10/8/24 6:41:41 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

      SC 13G/A - HARROW, INC. (0001360214) (Subject)

      2/13/24 5:25:53 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. sold $144,024 worth of shares (4,796 units at $30.03) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      6/5/25 4:05:47 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Opaleye Management Inc. sold $391,904 worth of shares (15,000 units at $26.13) (SEC Form 4)

      4 - HARROW, INC. (0001360214) (Issuer)

      5/14/25 4:56:15 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Large owner Opaleye Management Inc. sold $148,200 worth of shares (5,000 units at $29.64) (SEC Form 4)

      4/A - HARROW, INC. (0001360214) (Issuer)

      5/14/25 4:54:55 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    Financials

    Live finance-specific insights

    See more
    • Harrow Announces First-Quarter 2025 Financial Results

      First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 Cash flow from operations reached a record high of $19.7 million GAAP net loss of $(17.8) million Adjusted EBITDA of $(2.0) million Cash and cash equivalents of $66.7 million as of March 31, 2025 VEVYE® Access for All launch in mid-March is accelerating market share capture and revenue growth Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. Th

      5/8/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

      Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 9, 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast on th

      5/5/25 7:00:00 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

      Fourth-Quarter, Full-Year 2024, and Recent Highlights: Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023 GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024 Adjusted EBITDA of $22.5 million for Q4 2024, leading to Adjusted EBITDA of $40.3 million for FY 2024 IHEEZO® unit demand and VEVYE® prescriptions for Q4 2024 each increased over 40% over Q3 2024 VEVYE® Access for All program expected to drive continued market share expansion in 2025 TRIESENCE® transitional pass-through approved, significantly increasing addressable market opportunity H

      3/27/25 4:01:00 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HROW
    SEC Filings

    See more
    • SEC Form 10-Q filed by Harrow Inc.

      10-Q - HARROW, INC. (0001360214) (Filer)

      5/8/25 4:16:04 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harrow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HARROW, INC. (0001360214) (Filer)

      5/8/25 4:05:12 PM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Harrow Inc.

      DEFA14A - HARROW, INC. (0001360214) (Filer)

      4/25/25 8:01:18 AM ET
      $HROW
      Biotechnology: Pharmaceutical Preparations
      Health Care